Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
ConditionCardiac Amyloidosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age80+
SponsorGérond'if
About this trial
Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure with left ventricular hypertrophy (septum ≥ 12 mm) on echocardiography
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged ≥ 80 years
Hospitalised for decompensation of heart failure in the last 12 months
Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm)
Subjects able to undergo a bone scintigraphy scan
Disqualifiers
Subjects refusing to participate
Subjects admitted to palliative care unit.
Subjects under guardianship
Subjects with a definite diagnosis of cardiac amyloidosis
Trial population
Patients with cardiac amyloidosis expressed by a positive bone scintigraphy.
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Assessment of the number of patients with cardiac amyloidosis according bon scintigraphy
Time frame
At inclusionSecondary outcomes
1
Assessment of commorbidity risk according Charlson Comorbidity Index (CCI)
The Charlson Comorbidity Index (CCI) assesses the level of comorbidity by considering the level of severity of 19 predefined comorbid disorders and the number of disorders present among them.
Time frame
At inclusion2
Assessment of the degree of patient dependence according Katz Index of Independence in Activities of Daily Living (ADL)
Katz Index of Independence in Activities of Daily Living is an unabbreviated scale title. This Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Patients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
Time frame
At inclusion3
Measuring cognitive impairment according Mini-Mental State Examination (MMSE) score
The Mini-Mental State Examination is an unabbreviated scale title. This scale was developed as a brief screening tool to provide a quantitative evaluation of cognitive impairment and to record cognitive changes over time. The measure yields a total score of 30. A score of 23 or less is the generally accepted cutoff point indicating the presence of cognitive impairment. Levels of impairment have also been classified as none (24-30); mild (18-23) and severe (0-17)
Time frame
At inclusion4
Estimating the probability of neuropathic pain according "DN4 Questionnaire"
This questionnaire is an unabbreviated score title, it was originally developed and validated in French (4 items of neuropathic pain). It was identified as one of the most suitable neuropathic pain screening tools for clinical use: * Sensitivity: Ranges from 75-98%. Proven high sensitivity for central neuropathic pain and polyneuropathies. Sensitivity is low for tigeminal neuralgia. Moderate sensitivity for detecting a neuropathic component of pain in people with chronic pain. * Specificity: Ranges from 37-96%.
Time frame
At inclusion Source ClinicalTrials.gov